市場調查報告書

糖尿病視網膜病變市場 - 成長,趨勢,預測

Diabetic Retinopathy Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 921276
出版日期 內容資訊 英文 113 Pages
商品交期: 2-3個工作天內
價格
糖尿病視網膜病變市場 - 成長,趨勢,預測 Diabetic Retinopathy Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 113 Pages
簡介

全球糖尿病視網膜病變市場預計從2020年到2025年將以11.5%的年複合成長率擴大。糖尿病的盛行率上升,及老年人口的增加造成的失明,糖尿病視網膜病變手術器具的技術進步的增加等是市場成長的要素。

糖尿病視網膜病變(DR),成為全世界地視力降低主要的原因。對視力降低的進程的臨床性最重要的危險因素,是糖尿病的持續期間、高血糖、高血壓。血清葡萄糖和血壓的管理,有效預防DR造成的視力降低。因此,預計DR的普及率上升與對其認識和疑慮高漲,帶動在預測期間內的市場成長。

本報告提供糖尿病視網膜病變的世界市場調查,市場概要,各類型,各地區的市場趨勢,市場規模的變化與預測,市場促進、阻礙因素以及市場機會分析,競爭情形,主要企業的簡介等全面性資訊 。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 新加入廠商的威脅
    • 消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各類型
    • 增生性糖尿病視網膜病變
    • 非增生性視網膜症
  • 各管理方法
    • 抗VEGF藥
    • 眼內類固醇注射
    • 雷射手術
    • 玻璃體切除手術
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Alimera Sciences
    • Allergan plc
    • BCN Peptides
    • Genentech
    • Glycadia Pharmaceuticals
    • Kowa Group
    • Novartis AG
    • Oxurion NV.
    • Regeneron Pharmaceuticals Inc

第7章 市場機會及未來趨勢

目錄
Product Code: 67151

Market Overview

Global Diabetic Retinopathy market is expected to witness a CAGR of 11.5% during the forecast period. Certain factors that are driving the market growth include the rising prevalence of diabetes and blindness due to the same, growing geriatric population base, increasing technological advancements in diabetic retinopathy surgical instruments.

Diabetic retinopathy (DR) is a leading cause of vision-loss globally. According to a 2015 article, titled "Epidemiology of diabetic retinopathy, diabetic macular edema, and related vision loss", out of an estimated 285 million people with diabetes mellitus worldwide, approximately one third have signs of DR and of these, a further one-third of DR is vision-threatening DR. The most clinically important risk factors for progression to vision loss include duration of diabetes, hyperglycemia, and hypertension. Control of serum glucose and blood pressure have been shown to be effective in preventing vision loss due to DR. Hence, the rising prevalence of DR, along with the growing awareness and concern over it, are expected to drive the market growth over the forecast period.

Scope of the Report

Diabetic retinopathy refers to a diabetes complication that affects eyes, DR results in damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). Initially, diabetic retinopathy may cause no symptoms or only mild vision problems. But eventually, it can cause blindness.

Key Market Trends

Proliferative diabetic retinopathy is Expected to Hold Significant Market Share in the Type Segment

Proliferative diabetic retinopathy (PDR): PDR is the most advanced stage of diabetic retinopathy. At this stage, circulation problems deprive the retina of oxygen. As a result, new, fragile blood vessels can begin to grow in the retina and into the vitreous, the gel-like fluid that fills the back of the eye. The new blood vessels may leak blood into the vitreous, clouding vision. Symptoms include progressive loss of vision, particularly in those who are not properly followed or treated. The major risk factors for PDR include the duration of diabetes, since 30-34 years of diabetes increase the risk of retinopathy by 65%, according to the reports published by the Columbia University. Hence, the rising prevalence of diabetes is directly contributing to the further increase in the prevalence of PDR.

North America Dominates the Market and Expected to do Same in the Forecast Period

Over the past decade, the prevalence of diabetes in North America has increased. People with diabetes are at risk for diabetic retinopathy. Diabetic retinopathy is the leading cause of new cases of blindness among adults aged 20 to 74 years in the United States. More than 100 million U.S. adults are now living with diabetes or prediabetes, according to a new report published by the Centers for Disease Control and Prevention (CDC). The report finds that as of 2015, 30.3 million Americans - 9.4 percent of the U.S. population -have diabetes. Hence, all these factors are expected to contribute to market growth across the entire region.

Competitive Landscape

The global Diabetic Retinopathy market is moderately competitive and consists of a few major players. Companies like Alimera Sciences, Allergan plc, BCN Peptides, Genentech, Glycadia Pharmaceuticals, Kowa Group, Novartis AG, Oxurion NV., Regeneron Pharmaceuticals Inc, among others, which hold the substantial market share in the Diabetic Retinopathy market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Diabetes and Blindness Due to The Same
    • 4.2.2 Growing Geriatric Population Base
    • 4.2.3 Increasing Technological Advancements in Diabetic Retinopathy Surgical Instruments
  • 4.3 Market Restraints
    • 4.3.1 Lack of Skilled Ophthalmologists
    • 4.3.2 Extended Approval Time for Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Proliferative diabetic retinopathy
    • 5.1.2 Non-proliferative retinopathy
  • 5.2 By Management Approach
    • 5.2.1 Anti-VEGF Drug
    • 5.2.2 Intraocular Steroid Injection
    • 5.2.3 Laser Surgery
    • 5.2.4 Vitrectomy
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Alimera Sciences
    • 6.1.2 Allergan plc
    • 6.1.3 BCN Peptides
    • 6.1.4 Genentech
    • 6.1.5 Glycadia Pharmaceuticals
    • 6.1.6 Kowa Group
    • 6.1.7 Novartis AG
    • 6.1.8 Oxurion NV.
    • 6.1.9 Regeneron Pharmaceuticals Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS